Table 4 Outcomes metastatic melanoma

Total Doses

33.0 (29.0 – 41.75)

18.0 (12.5 – 28.0)

.001*

Total Cycles

6.0 (5.0 – 6.0)

2.0 (2.0 – 4.0)

<.001*

Doses per Cycle

6.4 (5.33 – 6.96)

7.0 (5.42 – 7.38)

.502*

Duration (months)

26.0 (18.25 – 56.25)

1.0 (0 – 4.0)

<.001*

Peak Fever (Celsius)

39.7 (38.5 – 40.3)

39.1 (38.4 – 39.3)

.158*

Peak ALC

3.75 (2.85 – 5.425)

2.9 (1.9 – 4.05)

.137*

Platelets

50.0 (37.25 – 93.0)

80.0 (69.5 – 133.0)

.015*

Autoimmune phenomenon

4 (50.0%)

4 (13.8%)

.049^†

Any Toxicity

5 (62.5%)

9 (31.0%)

.215^†

None

3 (37.5%)

20 (68.9%)

.215^†

Grade 3

3 (37.5%)

3 (10.3%)

.101^†

Grade 4

2 (25.0%)

6 (20.7%)

.1.0^†

Grade 5

--

--

--

Survived

6 (75.0%)

7 (24.1%)

.006^†

Survival Months

61.0

17.0

.001^¥